Tocilizumab-treated (anti-IL-6R) cognitively impaired mice showed cognitive improvement and reduction in Aβ immunoreactivity.30 Future studies should investigate the potential of anti-IL-6 therapies in obese patients with AD. Here, IL6 is linked to Alzheimer disease.